Wednesday, 25 March 2020

Chordoma Disease Market 2019 Share, Trend, Segmentation And Forecast To 2023

Market Scenario
Chordoma is a rare, slow-growing type of bone cancer. The increasing awareness programs about cancers led by WHO and UNICEF and the rising healthcare investment in the emerging markets are anticipated to exhibit more opportunities for the growth of the chordoma disease market trends.
The global chordoma disease market has been segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, the global chordoma disease market is segmented into biopsy, imaging, blood tests, and others. The imaging segment is further divided into x-ray, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, Positron Emission Tomography (PET) scanning, and bone scan.
On the basis of treatment, the global chordoma disease market is segmented into chemotherapy, radiation therapy, cryosurgery, surgical treatments, radiosurgery, targeted therapy, and others. The surgery segment is further classified into radical resections, sacral chordoma, spinal chordoma, skull base chordoma, and others. The chemotherapy segment is classified into methotrexate, doxorubicin, and others. Furthermore, the targeted therapy segment is divided into bevacizumab, erlotinib, and others.
On the basis of end-user, the global chordoma disease market is segmented into hospitals, clinics, cancer care centers, and others.
Regionally, the Americas chordoma disease market is segmented into two major regions, namely, North America and South America.
The Americas region holds the largest share of the global chordoma disease market owing to the increasing demand for targeted therapies and growing health concerns. As per an estimate by the American Cancer Society, about 3,300 new cases of bone cancer were diagnosed in 2016 with a death toll of about1490. Thus, the high prevalence of chondroid chordomas is the major hurdle in the market growth.
Key Players
Some of the key players in the global chordoma disease market are AstraZeneca plc (U.K.), Amgen, Inc. (U.S.), Actavis plc (U.S.), Bristol-Myers Squibb and Company (U.S.), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (UK), Novartis International AG (Switzerland), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Debiopharm Group (Switzerland), Bayer AG (Germany), Johnson & Johnson (U.S.), Merck & Co., Inc. (U.S.), Optivus Proton Therapy, Inc. (U.S.), ProCure Treatment Centers, Inc. (U.S.), Varian Medical Systems, Inc.(U.S.), Amura Holdings Ltd. (U.S.), Catena pharmaceuticals Inc. (U.S.), Celldex therapeutics Inc. (U.S.), Eckert & Ziegler BEBIG (Germany), Infinity Pharmaceuticals (U.S.), Medivir AB (Sweden), Merrion Pharmaceuticals Plc. (U.S.), and others.
Regional Analysis                    
The global chordoma disease market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas region accounted for the largest market share of the global chordoma disease market owing to the high prevalence of bone cancer in the region and aging population, along with high favorable reimbursement policies in the region. As per the American Cancer Society in 2017, about 3,260 people are projected to be diagnosed with primary bone cancer in the U.S. (1,820 men and boys and 1,440 women and girls).
The European chordoma disease market is anticipated to emerge as the second largest market owing to the development of the pharmaceutical and medical industries. According to the Cancer Research U.K. organization in 2014, about 580 new cases of bone sarcoma were found in the U.K.
The Asia Pacific region is expected to grow rapidly during the forecast period owing to less awareness regarding bone cancer among the population and less availability of effective treatment option for bone cancer in the region. For instance, in September 2016, Dr. Reddy's Laboratories entered into a strategic collaboration with Amgen for marketing and distributing Prolia (denosumab), Vectibix (panitumumab), and Xgeva (denosumab) in India.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.
Detailed Table of Contents:
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Disease Indication Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
...Continued
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Top Trends In Venous Blood Collection Devices Market By 2019

Market Scenario
The Global Venous Blood Collection Devices Market is expected to expand at a CAGR of 9.3% over the forecast period of 2019-2023, reveals Market Research Future (MRFR) in a detailed study.
Venous blood collection devices are vessels used for collection, sampling, and testing blood samples. These devices are easy to handle, provide mechanical protection as well as protection from contamination and radiation. Moreover, these blood collection devices offer the exact filling volume.
The global venous blood collection devices market trends are driven by the increasing diagnostics and screening for numerous diseases, increasing health awareness leading to growing demand for blood collection devices for sampling, and with the growing preference for disposable products. Product development can be an attractive strategy for expanding the global venous blood collection devices market.
However, restraints that are likely to hinder the growth of the venous blood collection devices market include risks associated with contamination, pressure on prices, and low-quality products from unknown manufacturers. 
The global burden of chronic diseases is increasing at an alarming rate which induces high demand for screening services and consequently boosts the growth of the global venous blood collection devices market. This further complemented by growing disposable income and high health awareness among consumers. To meet the massive demands, medical device manufacturers are endeavoring towards product improvement which jhas resulted in teh devleopment of advanced venous blood collection devices that can be used for safer blood collection. Furthermore expansdion in product oportfolio by key medical device manufacturers have resulted in teh consolidation of teh global venous blood collection devices market. On the other hand, the growth of the market might be undermined by risks related to contamination, pricing pressure, and substandard product from local manufacturers.
Key Players
Some of the key players in the global venous blood collection devices market are Becton, Dickinson and Company (U.S), Bio-Rad Laboratories, Inc. (U.S), NIPRO Medical Corporation (Japan), Qiagen NV (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Greiner Bio One International GmbH (Greiner Group) (Austria), Terumo Medical Corporation (Japan), Sekisui Chemical Co., Ltd. (Japan), Sarstedt AG & Co (U.S.), F.L. Medical (Italy), Narang Medical (India), Soya Green Tec Co., Ltd. (South Korea), Biosigma (U.S.), Vital Diagnostice (ELITech Group) (U.S.), Improve Medical Technology Co. Ltd. (U.S.), Hongyu Medical (China), SanLI (Myanmar.), KHB (U.S.), Zhejiang Gongdong Medical Technology Co., Ltd. (China), CDRICH (China), Radiometer Medical ApS (Danaher Corporation/ Danrad ApS) (Denmark), Medtronic Plc (U.S.), Fisher Scientific (Thermo Fisher Scientific Inc.) (U.S.), Kabe Labortechnik GmbH (Germany), Allegro Medical Supplies Inc. (Scrip Products Corporation) (U.S.), and others.
Segmentation
The global venous blood collection devices market has been segmented on the basis of type, material, application, and end-user.
On the basis of material, the global venous blood collection devices market is segmented into plastic, glass, stainless steel, ceramic, and others.
On the basis of type, the market is segmented into blood collection tubes, needles, vacuum blood collection system, microfluidic system, micro-container tubes, micro-hematocrit tubes, warming devices, and others. Other devices include venous cannula and blood bags. The blood collection tube is further sub-segmented into plasma separation tube, heparin tube, serum separating tube, EDTA tube, and others.
On the basis of application, the venous blood collection market is segmented into vein blood gas sampling and intraoperative blood salvage. Vein blood gas sampling is further sub-segmented into the diagnosis of disease and acid-base status monitoring.
On the basis of end-user, the global venous blood collection devices market is segmented into hospitals and clinics, the point of care, blood donation centers, diagnostic centers, and others.
Regional Analysis                     
The global venous blood collection devices market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure. Gulf nations such as the U.A.E. and Saudi Arabia are projected to drive the Middle Eastern and African market. The government has undertaken various awareness programs for safe blood transfusion procedures which are further improving the health conditions in underdeveloped regions of Africa.
The Americas region accounted for the largest market share of the global venous blood collection devices market owing to the fastest uptake of new surgical techniques and instruments in the North American region, thus driving the venous blood collection devices market. Moreover, the extensive use of screening techniques and high expenditure on health care in the U.S. is driving the market growth. The greater awareness in developed regions along with the good reimbursement scenario drive the Americas venous blood collection devices market.
The European region accounted for the second largest market owing to high income and healthcare penetration. The Asia Pacific region is expected to increase during the forecast period owing to the growing healthcare sector in leading regions such as China and India. The major driving factors of the venous blood collection devices market are the increasing geriatric population, growth in demand for safe blood assortment technologies, increase in demand for improved blood sampling techniques, and increase in preference towards disposable products for the laboratory.
Detailed Table of Contents:
Table Of Content
  1. Report Prologue
  2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
  1. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
  1. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
  1. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Epilepsy Diagnosis & Treatment Market 2019 Share, Trend, Segmentation And Forecast To 2023

Synopsis of the Global Epilepsy Diagnosis & Treatment Market
Increasing prevalence of epilepsy, rising number of traumatic brain injury cases, growing geriatric population, and rising healthcare expenditures are the major drivers for the global epilepsy diagnosis and treatment market trends. However, high cost of therapeutic surgeries, low per capita healthcare expenditure, and lack of awareness for the disease in emerging economies are estimated to restrain the market growth during the projected period. The global epilepsy diagnosis and treatment market is estimated to grow at an approximate CAGR of 6.3% during the forecast period.
Segmentation
The global epilepsy diagnosis and treatment market is segmented on the basis of type, diagnosis, treatment, and end-user. On the basis of type, the market is segmented into idiopathic, cryptogenic, symptomatic, and others. On the basis of diagnosis, the market is segmented into neurological exam, blood test, imaging, and others. The imaging segment is sub-segmented into electroencephalogram, computerized tomography, magnetic resonance imaging, positron emission tomography, and others. On the basis of treatment, the market is segmented into medication, surgery, brain stimulation, and others. The medication segment is sub-segmented into acetazolamide, carbamazepine, clobazam, and others. The surgery segment is sub-segmented into hemispherectomy, corpus callosotomy, resection surgery, and others. The brain stimulation segment is sub-segmented into deep brain stimulation, responsive neurostimulation, and others. On the basis of end user, the market is segmented into hospitals & clinics, diagnostic centers, and others.
Regional Analysis
The Americas dominate the global epilepsy diagnosis and treatment market, which can be attributed to the presence of a well-developed healthcare sector and huge patient population within the region. Moreover, increasing number of head trauma cases boosts the American market. Europe holds the second largest market share owing to the availability of funds for research, presence of a well-developed healthcare sector, and government support. Followed by Europe, the Asia Pacific region is projected to be the fastest growing region for the global epilepsy diagnosis and treatment market. Presence of developing healthcare sector, along with emerging economies of the Asia Pacific region boosts the market growth. The Middle East & Africa has the least share in the global epilepsy diagnosis and treatment market, owing to the low per capita healthcare expenditures, lack of awareness for the disease, and stringent government policies, especially in the African region. On the other hand, the Middle East region within the Middle East & Africa is estimated to be fastest growing region due to growing healthcare expenditures and presence of the developed economies, such as Kuwait, Qatar, Dubai, and others.
Key Players
The key players for the global epilepsy diagnosis and treatment market are Pfizer, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), UCB Pharma Ltd. (U.K), Abbott (U.S.), GlaxoSmithKline plc (U.K), Novartis International AG (Switzerland), Sanofi S.A. (France), Shire (Republic of Ireland), Medtronic (U.S.), NeuroWave Systems Inc. (U.S.), Natus Medical Incorporated. (U.S.), Siemens Ltd. (Germany), and others.
Detailed Table Of Contents
1 Introduction
1.1 Definition
1.2 Scope Of Study
1.2.1 Research Objective
1.2.2 Assumptions & Limitations
1.2.2.1 Assumptions
1.2.2.2 Limitations
1.3 Market Structure:
2 Research Methodology
2.1 Research Process:
2.2 Primary Research
2.3 Secondary Research:
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porters Five Forces Model
4.2 Bargaining Power Of Suppliers
4.3 Bargaining Power Of Buyers
4.4 Threat Of New Entrants
4.5 Threat Of Substitutes
4.6 Intensity Of Rivalry
…TOC Continued!
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Global Ebstein’s Anomaly Market Production, Capacity, Revenue, Price, Gross Margin Analysis And Forecast 2019-2023

Market Scenario:
Ebstein's anomaly is a rare congenital disease that occurs due to improper development of the tricuspid valve in the first eight weeks of fetal growth. This disorder occurs when the tricuspid valve that divides the two chambers of the right side of the heart does not form correctly.
Ebstein's anomaly may be due to many factors, including genetics and the environment. Children born in a family with a history of heart defects may be more likely to have Ebstein's anomaly. The mother's exposure to certain medications, such as lithium, can lead to Ebstein's anomaly in the child.
The global Ebstein’s Anomaly market is driven by the increasing number of congenital heart diseases and growing population; growing market players has increased the scope of Ebstein’s Anomaly market. Technological advancements, owing to which new and advanced products are being launched in the market, is another factor propelling the growth of this market.
However, varied stringency of regulatory procedures across the globe and the presence of complex regulatory procedures may hinder the growth of this market.
The global Ebstein’s Anomaly market is expected to grow at a CAGR of 9.0% during the forecast period.
 Intended Audience
  • Pharmaceutical Manufacturers and Suppliers
  • Medical Research Laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Potential Investors
Segments  
The global Ebstein’s Anomaly market is segmented on the basis of treatment, diagnosis and end users.
On the basis of the treatment, the market is segmented medications and surgical treatment. Surgical Treatment is further segmented into tricuspid valve repair, tricuspid valve replacement, closure of the atrial septal defect, and maze procedure.
On the basis of diagnosis Ebstein’s Anomaly market is segmented into echocardiogram, electrocardiogram (ECG) chest x-ray, cardiac MRI, Holter monitor, pulse oximetry, exercise stress test, electrophysiology study, and cardiac catheterization.
On the basis of end users, the market is segmented into hospitals & surgical centers, and specialty clinics.
Regional Analysis
North America Ebstein’s Anomaly market is rapidly growing in the American region. On a regional basis, the Americas is segmented into North America and South America. North America is segmented into the U.S. and Canada. Increasing number of congenital disorders and growing  population has increased the scope for the Ebstein’s Anomaly market in North America. According to CDC (Centre for Disease Control), it was estimated that about 1 million U.S. children and about 1.4 million U.S. adults were living with CHDs.  Additionally, CHDs affect nearly 1% of―or about 40,000―births per year in the United States.
Europe is the second largest market and holds a healthy share in the global Ebstein’s Anomaly market. The European market is expected to grow steadily during the forecast period owing to the skilled professionals and availability of advanced and accessible treatment facilities. Additionally, wide research and development activities for the treatment of rare disease and increasing government funding boost the market growth.  
Asia Pacific is expected to be the fastest growing market. Increasing prevalence of chronic diseases such as diabetes is the major driver for the market growth. India is the fastest growing region owing to the increasing population. Rising awareness about the health and availability of new treatment methods drive the market in this region. Rising healthcare expenditure and overall growth of healthcare diagnostic and treatment industry also drives the market.
The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, United Arab Emirates is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers.
Key Players       
Some of the key players in Ebstein’s Anomaly Market are Ebstein’s Anomaly market are Abbott Vascular, Boston Scientific Corporation, Cordis Corporation, Edwards Lifesciences, Ge Healthcare, Gore Medical, Medtronic, Inc., Numed, Inc., Siemens Healthcare, St. Jude Medical, and Toshiba Corporation among others.
Detailed Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
...TOC Continued!
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Autoimmune Disease Treatment Market, Segments, Growth And Value Chain 2019

Autoimmune Disease Treatment Market Size, Share 2019 | Global Industry Research Reports, Growth Opportunities, Top Key Vendors and Regional Analysis till 2023
Market Research Future (MRFR)’s latest assessment reveals that the global autoimmune disease treatment market is expected to thrive at 11.2% CAGR during the forecast period 2017 to 2023. The market signifies massive unmet needs for diagnosis. It is projected to favor the expansion of the global market by bringing advanced, precise and effective drugs and treatments.
Autoimmune Disease Treatment Market Research Information: By Disease Type (Localized, Systemic), Diagnosis (Elisa, Dot Blot, Agglutination, Others), Therapeutic Products (Drugs, Monitoring Equipment), Distribution Channel – Global Forecast Till 2023
Autoimmune disease is a medical condition that causes abnormalities in the immune response and triggers damage to the healthy body tissues. The increasing prevalence of autoimmune diseases all over the world is generating high demand for effective treatments in the global market. As per the report published by Market Research Future (MRFR), the global autoimmune disease treatment market size is anticipated to expand remarkably at a noteworthy CAGR of 11.2% during the forecast period of 2017-2023.
Autoimmune diseases are diseases caused by the immune system mistaking the body’s own tissue for foreign tissues and attacking it. This can happen due to a number of complications within the immune system and can have disastrous consequences on the health of the individual. Some of the most widely prevalent autoimmune diseases include rheumatoid arthritis, lupus, and multiple sclerosis. Growing awareness about autoimmune diseases and their treatment is likely to be a major driver for the global autoimmune disease treatment market over the forecast period. While autoimmune diseases have always been present among human populations, their sporadic appearance and lack of infectiousness made them relatively minor subjects of study compared to other, more imminent threats. The growing prevalence of autoimmune diseases in modern times has led to growing awareness about the disease and is likely to remain the key driver for the autoimmune disease treatment market over the forecast period.
Growing development of effective treatments for a number of autoimmune diseases is likely to be a major driver for the global autoimmune disease treatment market over the forecast period. Autoimmune diseases can be hard to treat effectively, as treating them effectively means shutting down or slowing down the operations of the body’s immune system. While this may be an effective way of combating autoimmune diseases, this can also leave the body vulnerable to other infections and diseases that can make the most of the body’s temporary weakness. The use of genetic components in treating autoimmune diseases is a new aspect gained by the autoimmune disease treatment market in the last few years and is likely to remain a key part of the market over the forecast period due to the increasing awareness about its effectiveness and safety.
Competitive Dashboard:
Some of the prominent players profiled in this MRFR report are
  • Abbott Laboratories,
  • Genentech Inc.,
  • Bayer Schering Pharma AG,
  • Amgen Inc.,
  • Biogen Idec Inc.,
  • Chugai Pharmaceutical Co. Ltd.,
  • Danaher,
  • Bio-Rad,
  • Elan Corporation Plc,
  • Hoffmann-La Roche AG,
  • GlaxoSmithKline Plc,
  • HYCOR Biomedical,
  • Eli Lilly and Company,
  • Johnson & Johnson Inc.,
  • Siemens,
  • Squibb Company,
  • Merck & Co. Inc.,
  • Thermo Fisher Scientific.
Segmental Analysis:
By disease type, the global autoimmune disease treatment market has been segmented into localized, and systemic. The localized segment is further sub-segmented into multiple sclerosis, inflammatory bowel disease, diabetes, and other. The systemic segment is sub-segmented into rheumatoid arthritis, psoriasis, lupus, and others.
By diagnosis, the autoimmune disease treatment market has been segmented into ELISA, dot blot, line blot, agglutination, double immune diffusion, western blotting, multiplex immunoassay, and others.
By therapeutic products, the global autoimmune disease treatment market has been segmented into drugs and therapeutic and monitoring equipment. The drugs segment is further sub-segmented into biologics, immunosuppressant, anti-inflammatory drugs, corticosteroids, and non-steroidal anti-inflammatory drugs.
By distribution channel, the autoimmune disease treatment market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.
Regional Outlook:
The Americas dominate the autoimmune disease treatment market owing to the rising cases of autoimmune diseases, and high healthcare expenditure. As per the data suggested by Centers for Disease Control and Prevention in 2015, the total healthcare expenditure in the U.S. was reported to be USD 3.2 trillion, whereas, hospital care accounted for a share of 32.3%.
Europe holds the second position in the autoimmune disease treatment market. It is expected that the financial support provided by the government bodies for research & development and amendments in reimbursement policies in the healthcare is likely to drive the European market
Owing to a huge patient pool and developing healthcare technology, Asia Pacific is the fastest growing autoimmune disease treatment market. Healthcare expenditure is also found to be escalating in various Asia Pacific countries. The Australian Institute of Health and Welfare suggested that in the year 2015-2016, the total healthcare expenditure was USD 170.4 billion, which is around 3.6% higher than the expenditure during 2014-2015.
The Middle East & Africa holds the lowest market due to poor medical facilities, and lack of technical knowledge.
Industry News:
  • In January 2019, Cabaletta Bio, launched out of the University of Pennsylvania, has raised USD 50 Mn for the treatment of for cell-based autoimmune disease.
  • In January 2019, Banner Life Sciences LLC, a privately held specialty pharmaceutical company, has received tentative approval by the U.S. Food and Drug Administration (FDA) for BAFIERTAM developed for the treatment of relapsing forms of Multiple Sclerosis.
Detailed Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
...TOC Continued!
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Amblyopia Market - Demand, Growth, Opportunities And Analysis Of Top Key Player Forecast To 2023

Amblyopia is an eye disorder which leads to decreased vision in one or both the eyes due to suppressed input from the brain. The most common cause of amblyopia is a refractive error in one or both eyes, or it might even occur due to muscle imbalance. The other cause of amblyopia is if the infant is born with a cataract, which causes cloudy images. There are four types of amblyopia, namely, Strabismus Amblyopia, Refractive Amblyopia, Deprivation Amblyopia, and Reverse Amblyopia. The global prevalence rate of Amblyopia is 2 to 3% of the infant population. Amblyopia market is driven by growing incidence of ophthalmological disorders such as cataracts, macular degeneration, glaucoma, and refractive errors. According to reports published by the United Kingdom Statistics Authority, in 2015, around 15,900 people were registered as visually impaired. Moreover, according to the Journal of Ophthalmology, as of 2014 there were around 28 million visually impaired people in the European region. With the increasing prevalence, there is increasing in the advancement of treatment and hence influencing the growth of the Amblyopia market size. 
Amblyopia, commonly known as lazy eye, is a vision impairment disorder, in which one or both the eyes have reduced or no vision. Amblyopia can begin during infancy or early childhood. Amblyopia requires detection and diagnosis early in childhood, which otherwise can lead to blindness during later life. On the basis of type, amblyopia can be divided into, Strabismic amblyopia, Refractive amblyopia, Deprivation amblyopia, and Reverse Amblyopia.
Global amblyopia market is expected to grow at a CAGR of 3.80% during the forecast period 2017-2023.
Key Players                                                                                                         
  • Amblyoptica (Holding) Pty Ltd,
  • Amblyotech, Inc,
  • Good-Lite Co,
  • Vivid Vision, Inc.,
  • Cooper Vision,
  • Johnson & Johnson,
  • Novartis AG.,
  • Carl Zeiss AG,
  • HOYA Corporation,
  • Krafty Eye Patches¸
  • Fresnel Prism and Lens Co.,
  • Hilco Vision,
  • McKesson Corporation
Segmentation                      
The global amblyopia market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis the type, it is segmented into strabismus amblyopia, refractive amblyopia, deprivation amblyopia, reverse amblyopia, and other.
On the basis of the diagnosis, it is segmented into visual acuity tests, photo screening, Bruckner test and others.
On the basis of the treatment, it is segmented into eye patches, atropine drops, glasses, video game and others.
On the basis of the end-user, it is segmented into hospitals & pharmacies, ophthalmic clinics, and others.
Regional analysis
The global amblyopia market, on the basis of region, is divided into the Americas, Europe, Asia Pacific and the Middle East & Africa. The Americas accounted for the largest amblyopia market share of 37.9% in 2016 for global amblyopia market. This large share is majorly attributed due to the increasing prevalence of ophthalmological disorders, the presence of major manufacturers, increasing technological advancement and high healthcare expenditure. Europe accounts for the second largest market share, whereas Asia Pacific is expected to grow at the fastest rate with 4.35% CAGR for the forecast period. With lots of opportunity and continuously growing economies, the presence of huge patient population, rapid development in technology and presence of a huge opportunity for the development the region is expected to be the fastest growing region. The Middle East & Africa is growing at a slow pace, and the low income accounted for the least market share in 2016 but is expected to grow in the coming future.

Detailed Table of Contents:
1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3 Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
...Continued!
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Posted by at No comments:

Acute Sinusitis Market Value Share, Supply Demand, Share And Value Chain 2019

Acute Sinusitis Market Information: By Diagnosis (Nasal Endoscopy, Imaging Test, Laboratory Test, Allergy Testing), Treatment (Saline Nasal Spray, Nasal Corticosteroids, Decongestants, OTC Pain Relievers), End-User (Hospitals)- Global Forecast Till 2023
Synopsis of the Global Acute Sinusitis Market
The Acute Sinusitis Market is mainly driven by the increasing prevalence of sinusitis across the globe and the increasing demand for diagnostic services. Additionally, technologically advancement and development in healthcare and upcoming Acute Sinusitis Market trends are also the factors driving the market growth. However, there is a need to create awareness about the disease and its diagnosis, especially, in the developing countries.
Also known as acute rhinosinusitis, acute sinusitis causes inflammation and swelling of cavities around the nasal passage. It is mostly caused by the common cold. Nasal obstruction, drainage of a thick, yellow or greenish discharge and pain, tenderness, and swelling around the nose, eyes, and forehead are the major symptoms of acute sinusitis. Other symptoms of the disease are ear pressure, bad breath, headache, cough, aching in your upper jaw and teeth, fatigue, and fever. The complications due to acute sinusitis are found to be less common. However, chronic sinusitis, meningitis, partial or complete loss of sense of smell, and vision problems are some of the major complications.
Global acute sinusitis market is expected to grow at a CAGR of 6.2% during the forecast period.
Key Players       
Some of the key players in this market are Sanofi (France), Abbott (U.S.), Bayer AG (U.S.), Eli Lilly and Company (U.S.), Bristol-Myers Squibb (U.S.), Merck & Co, Inc. (U.S.), AstraZeneca Plc (U.K), Reddy’s Lab (India), Novartis AG (Germany), and others.
Segmentation                                                                                                                                            
The global acute sinusitis market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, the market is segmented into nasal endoscopy, imaging tests, laboratory tests, and allergy testing. Imaging tests are further segmented into CT scan and MRI.
On the basis of treatment, the market is segmented into saline nasal spray, nasal corticosteroids, decongestant, OTC pain relievers, allergy shots, antibiotics, and others.
On the basis of end-user, the market is segmented into hospitals and clinics, research centers, and others.
Regional Analysis
The Americas leads the global acute sinusitis market with North America being the largest. The rising prevalence of chronic diseases in the U.S. and technological advancements in diagnostic testing fuel the growth of the market in North America. According to the Center for Disease Control and Prevention (CDC), in the U.S., 29.4 million people suffer from acute sinusitis. Additionally, there is an increase in the direct spending by the U.S. population for sinusitis management including medications, outpatient and emergency department visits, and ancillary tests and procedures.
Europe is the second largest market for acute sinusitis. The increasing demand for laboratory test and allergy testing, with an increase in various types of laboratory testing fuel the growth of the market. Furthermore, there are various other factors driving the growth of the market such as increasing focus on diagnostic testing for both acute and chronic illnesses and increasing expenditure on research and development activities by countries such as Germany, France and the U.K. Additionally, the increasing focus on development of innovative technologies and overall growth of healthcare diagnostics in this region also contribute to the growth of the market.
The Asia Pacific acute sinusitis market is expected to exhibit a huge growth potential which is mainly driven by the increasing awareness about acute sinusitis and the increasing demand for a skin test for its diagnosis. Furthermore, the increasing demand for laboratory testing devices and a huge development in the medical device sector fuel the growth of the market in this region. Additionally, the market is also driven by the increasing focus of key players on targeting major geographies in Asia Pacific such as India, Australia, and the Republic of Korea. Additionally, the increasing number of patients suffering from acute sinusitis and the availability of various treatment options for the disease drive the growth of the market.  India, China, and Japan are the major contributors to the growth of the market due to an increase in the number of healthcare institutes such as hospitals and clinics and availability of skilled workforce.
In the Middle East, the market is mainly driven by the increasing importance of diagnosis and treatment for sinusitis and the growth of the healthcare industry in countries such as the United Arab Emirates (U.A.E.) and Saudi Arabia. In Africa, the demand for primary care services and the increasing prevalence of acute and chronic diseases are the major factors driving the market growth.
Detailed Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
  1. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
  1. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
…TOC Continued!
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Subscribe to: Posts (Atom)